Lymph Node Swelling: Labs, Diagnosis, and Next Steps

What Lymph Node Swelling Actually Means

Lymph nodes are small, bean-shaped structures distributed along the lymphatic system. They filter lymph fluid and house immune cells that respond to pathogens, damaged cells, and abnormal proteins. Swelling (lymphadenopathy) signals that the immune system is actively responding to a stimulus.

Localized vs. Generalized Lymphadenopathy

Clinicians divide lymphadenopathy into two categories. Localized lymphadenopathy affects one anatomic region and accounts for about 75% of all presentations [1]. Generalized lymphadenopathy, defined as enlargement in two or more non-contiguous regions, suggests a systemic process such as HIV, systemic lupus erythematosus (SLE), or disseminated malignancy [2].

How Nodes Signal Their Cause

The texture, mobility, and tenderness of a swollen node offer diagnostic clues before any lab is drawn. Tender, soft, mobile nodes typically reflect infection. Hard, fixed, non-tender nodes raise concern for malignancy. Rubbery, matted nodes suggest lymphoma. A 2024 BMJ Best Practice review emphasized that clinical context, including patient age, node location, and duration, drives the pre-test probability of serious disease more reliably than any single lab value [2].

Common Causes of Lymph Node Swelling

The differential diagnosis is broad. Sorting causes by frequency in a primary-care population helps clinicians and patients set realistic expectations.

Infections

Upper respiratory tract infections, pharyngitis, dental abscesses, skin infections, and otitis media account for the majority of localized cervical, submandibular, and preauricular lymphadenopathy. Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are classic causes of generalized lymphadenopathy in adolescents and young adults. Tuberculosis remains a leading cause of chronic lymphadenopathy in endemic regions; a meta-analysis in The Lancet Infectious Diseases found that tuberculous lymphadenitis accounted for up to 43% of peripheral lymphadenopathy cases in high-burden countries [3].

Autoimmune and Inflammatory Conditions

SLE, rheumatoid arthritis, sarcoidosis, and Kikuchi-Fujimoto disease can all present with lymphadenopathy. In SLE, lymph node enlargement occurs in 12% to 50% of patients over the disease course [4]. Sarcoidosis frequently involves bilateral hilar lymph nodes, visible on chest imaging before any peripheral node is palpable.

Malignancy

Lymphoma (both Hodgkin and non-Hodgkin), leukemia, and metastatic solid tumors are the diagnoses clinicians must not miss. A prospective Dutch study of 2,556 patients referred to general surgery for unexplained lymphadenopathy found malignancy in only 1.1% of those presenting in primary care, but the rate climbed to 17% among patients referred to a specialist [5]. Age matters: in patients over 40, the probability of malignancy in a persistently enlarged node roughly doubles compared to younger adults.

Medications

Phenytoin, allopurinol, atenolol, and certain antibiotics (notably cephalosporins) can cause drug-induced lymphadenopathy. This diagnosis is often missed because clinicians do not review the medication list early enough.

The Diagnostic Workup: Which Labs to Order

A targeted lab panel, guided by clinical suspicion, avoids both unnecessary testing and dangerous omissions.

First-Line Blood Tests

For any patient with lymphadenopathy lasting more than two weeks without an obvious infectious source, the following panel is standard:

• Complete blood count (CBC) with differential. Leukocytosis with neutrophilia suggests bacterial infection. Lymphocytosis with atypical lymphocytes points toward EBV or CMV. Cytopenias raise concern for marrow infiltration or autoimmune disease.
• C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). Elevated inflammatory markers support an infectious or inflammatory cause but lack specificity.
• Lactate dehydrogenase (LDH). Elevated LDH, while non-specific, correlates with high tumor burden in aggressive lymphomas. The International Prognostic Index for non-Hodgkin lymphoma uses LDH as one of five prognostic variables [6].
• Peripheral blood smear. Manual review can identify blast cells (leukemia), atypical lymphocytes (viral syndromes), or rouleaux formation (multiple myeloma).

Second-Line and Targeted Tests

Based on clinical suspicion, additional labs may include:

• EBV and CMV serologies if infectious mononucleosis is suspected.
• HIV antigen/antibody test. The CDC recommends routine HIV screening in all patients aged 13 to 64, and acute HIV seroconversion commonly presents with generalized lymphadenopathy [7].
• Antinuclear antibody (ANA) and anti-dsDNA if SLE or another connective tissue disease is suspected.
• Uric acid and calcium. Elevated calcium can indicate sarcoidosis or lymphoma.
• Tuberculin skin test (TST) or interferon-gamma release assay (IGRA) in patients with risk factors for tuberculosis.
• Toxoplasma IgG/IgM if the patient reports cat exposure or consumption of undercooked meat.

A Decision Framework for Lab Ordering

A practical triage approach, adapted from the American Academy of Family Physicians (AAFP) lymphadenopathy evaluation algorithm, organizes the workup by acuity [8]:

1. Acute (<2 weeks), localized, tender, with clear infectious source: Treat the infection. No labs needed unless the node does not resolve.
2. Subacute (2 to 6 weeks), localized, no obvious cause: Order CBC, CRP, LDH, peripheral smear. Consider EBV/CMV serologies and HIV testing.
3. Persistent (>6 weeks) or with red flags (supraclavicular, fixed, B symptoms): Proceed directly to imaging and probable biopsy. Do not wait for lab results to delay referral.
4. Generalized lymphadenopathy: Broad panel including CBC, CRP, LDH, ANA, HIV, EBV/CMV, hepatitis B/C serologies, and peripheral smear. Consider CT imaging early.

Imaging: When and What to Order

Imaging clarifies the size, number, and anatomic relationships of enlarged nodes, especially when they are deep or when the clinical picture is ambiguous.

Ultrasound

Ultrasound is the first-line imaging modality for superficial lymphadenopathy. It distinguishes reactive from suspicious morphology based on the hilum, cortical thickness, and vascularity pattern. A preserved fatty hilum is reassuring. Cortical thickening greater than 3 mm or loss of the hilum raises concern [9]. Ultrasound is non-irradiating, inexpensive, and widely available.

CT and PET-CT

Contrast-enhanced CT is the standard for evaluating deep lymphadenopathy (mediastinal, retroperitoneal, mesenteric). PET-CT with fluorodeoxyglucose (FDG) is reserved for staging confirmed or highly suspected lymphoma. The Lugano classification, published in the Journal of Clinical Oncology, now uses PET-CT as the preferred modality for staging FDG-avid lymphomas [10].

MRI

MRI is used selectively, typically for head and neck lymphadenopathy or when CT contrast is contraindicated. Diffusion-weighted imaging (DWI) can help differentiate benign from malignant nodes based on apparent diffusion coefficient (ADC) values.

Biopsy: When It Becomes Necessary

No blood test or imaging study can definitively rule out lymphoma. Biopsy remains the gold standard for tissue diagnosis.

Indications for Biopsy

The AAFP and multiple hematology guidelines recommend biopsy when any of the following are present [8]:

• Node size greater than 2 cm (some guidelines use 1.5 cm).
• Supraclavicular location (associated with malignancy in up to 34 to 50% of cases in adults).
• Node persisting or enlarging beyond 4 to 6 weeks despite empiric treatment.
• Hard, fixed, or matted nodes.
• B symptoms: unexplained fever above 38°C, drenching night sweats, or unintentional weight loss exceeding 10% of body weight over 6 months.
• Abnormal CBC, elevated LDH, or suspicious findings on imaging.

Excisional vs. Fine-Needle Aspiration

Excisional biopsy, removing the entire node, is preferred when lymphoma is suspected because it preserves tissue architecture necessary for accurate subtyping. Fine-needle aspiration (FNA) has a sensitivity of approximately 85 to 90% for metastatic carcinoma but performs poorly for lymphoma diagnosis. A study in the American Journal of Clinical Pathology found that FNA missed the diagnosis in 17% of lymphoma cases that were correctly identified on subsequent excisional biopsy [11]. Core-needle biopsy is an acceptable intermediate when excisional biopsy is technically difficult.

Red Flags: When Swollen Lymph Nodes Need Urgent Evaluation

Certain features should prompt same-week or same-day specialist referral rather than a watch-and-wait approach.

High-Risk Node Locations

Supraclavicular nodes carry the highest malignancy risk of any peripheral site. Right supraclavicular nodes drain the mediastinum and lungs; left supraclavicular nodes (Virchow node) drain the thoracic duct and can signal abdominal or pelvic malignancy. Posterior cervical nodes in older adults also carry elevated risk.

Systemic Warning Signs

The combination of lymphadenopathy with B symptoms (fever, night sweats, weight loss) mandates urgent hematology referral. Rapid node growth over days to weeks, especially in a patient over 40, shifts the probability sharply toward aggressive lymphoma or metastatic disease.

Concerning Lab Patterns

An LDH level more than twice the upper limit of normal, unexplained cytopenias on CBC, or the presence of blast cells on peripheral smear all warrant urgent action. Dr. Kieron Dunleavy, an oncologist at the National Cancer Institute, has noted: "A markedly elevated LDH in the setting of rapidly enlarging lymphadenopathy should be treated as a hematologic emergency until proven otherwise" [6].

Treatment: Addressing the Underlying Cause

Lymph node swelling is a sign, not a disease. Treatment targets the underlying condition.

Infectious Causes

Bacterial lymphadenitis responds to antibiotics directed at the likely pathogen. For cervical lymphadenitis secondary to dental or pharyngeal infection, amoxicillin-clavulanate (875/125 mg twice daily for 10 days) is a common first-line choice. Abscess formation may require incision and drainage. Viral lymphadenopathy (EBV, CMV, acute HIV) is managed supportively, and nodes typically return to baseline within 4 to 8 weeks.

Autoimmune Causes

Treatment of the underlying autoimmune disease (e.g., hydroxychloroquine and immunosuppressants for SLE) generally resolves associated lymphadenopathy. Persistent or disproportionate node enlargement in a patient with known autoimmune disease should still prompt biopsy to exclude lymphoma, which occurs at higher rates in SLE and Sjögren syndrome [4].

Malignant Causes

Treatment is histology-specific. Hodgkin lymphoma, for example, has a 5-year overall survival exceeding 85% with modern chemotherapy regimens such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) [12]. Non-Hodgkin lymphoma outcomes vary widely by subtype. Metastatic solid tumors found via lymph node biopsy are treated based on the primary tumor site.

Drug-Induced Lymphadenopathy

Discontinuation of the offending medication typically leads to resolution within 2 to 4 weeks. No specific treatment is needed if the diagnosis is confirmed.

Monitoring and Follow-Up

Even when initial evaluation is reassuring, structured follow-up prevents missed diagnoses.

The 4-to-6-Week Rule

The AAFP recommends re-evaluation at 4 to 6 weeks if an initially benign-appearing node has not resolved [8]. At the follow-up visit, repeat physical exam and CBC. If the node has enlarged or new nodes have appeared, proceed to imaging and biopsy.

Post-Biopsy Surveillance

Patients with reactive or benign biopsy results should have a single follow-up exam at 3 months to confirm resolution. Those with negative biopsies but persistent clinical concern may warrant repeat biopsy, as sampling error (particularly with FNA) can produce false negatives.

When to Repeat Labs

Repeat LDH and CBC at the 4-to-6-week follow-up. If both have normalized and the node is shrinking, observation can continue. Rising LDH or new cytopenias change the management plan.

The Endocrine Society's 2023 clinical practice guideline reminds clinicians that thyroid nodules can present as cervical lymphadenopathy, and thyroid function tests (TSH, free T4) should be included in the workup of anterior cervical nodes, particularly in women aged 30 to 60 [13].